Atmo Biosciences has announced the appointment of experienced medical device executive Chris Bertrand to its board and the establishment of an office in San Diego.
The company is commercialising the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function.
It is preparing to launch a multi-site pivotal study for a US FDA submission in support of using its gas-sensing capsule to assess gastrointestinal motility.
Mr Bertrand has three decades of experience working in the medical device industry, including 10 years as President of Latin America for Cochlear.
Atmo Biosciences' chair Kate Hill said Mr Bertrand’s commercial experience and medical device industry expertise would be invaluable as it moves toward commercialisation.
“I’m delighted to welcome Chris to the Atmo Board. Chris has global experience and deep connections in the American medical device industry and other markets. His knowledge and fantastic track record of growing profitable businesses will be very important as we take the first steps towards US market launch,” said Ms Hill.
Mr Bertrand said, “Atmo has a unique product that has the potential to hugely improve the lives of millions of sufferers of gastrointestinal disorders. I’m looking forward to helping guide Atmo through the next phase of commercialisation.”
Atmo Biosciences said it is now a resident company of the life science incubator, Johnson & Johnson Innovation – JLABS..
Atmo Biosciences CEO Malcolm Hebblewhite added, “The establishment of the San Diego office is an important step as Atmo increases its focus on the US market. Not only does it provide us with a US base for our pivotal study, it also gives us the opportunity to connect and collaborate with other life science companies co-located at JLABS @ San Diego. The focus on microbiome, precision medicine and therapeutic potential solutions makes this site a perfect fit for Atmo.”